Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation

NAEnrolling by invitationINTERVENTIONAL

Enrollment

226

Participants

Timeline

Start Date

August 21, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Hepatitis B ReactivationHematopoietic Stem Cell TransplantationAntiviral DrugHBV

Interventions

DRUG

Baracle Tab.®

The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.

Trial Locations (1)

Jeong Won Jang, Seoul

All Listed Sponsors

lead

Seoul St. Mary's Hospital

OTHER